Alnylam Pharmaceuticals Stock News

The RNAi drugmaker hits the mark in a rare form of heart failure.

Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study. The post Alnylam Pharmaceuticals Is On Track To Hit A Record High —

Shares of Alnylam Pharmaceuticals Inc. ALNY, +1.44% soared 57.0% in premarket trading on Wednesday after the company said its investigational RNAi therapeutic for a type of heart failure met the prima

After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.

After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corpor

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Results from the APOLLO-B study are due any day now and will significantly impact sentiment around ALNY shares, as well as the revenue potential of Onpattro. A clearly successful outcome could quadrup

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0

Upgrades For The Shyft Group Inc (NASDAQ:SHYF), DA Davidson upgraded the previous rating of Neutral to Buy. Shyft Group earned $0.06 in the first quarter, compared to $0.36 in the year-ago quarter. Th

Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.